Square is set to finish its phased rollout of Bitcoin payments for eligible U.S. sellers by November 10. The rollout began on March 30, automatically enabling Bitcoin payments for qualifying sellers without requiring requests. Customers can pay using the Lightning Network, while sellers receive payments in U.S. dollars by default but can opt to receive Bitcoin. Sellers can also convert up to 50% of daily sales into Bitcoin. Bitcoin payment processing is free until December 31, 2026, after which a 1% fee will apply. This expansion could increase Bitcoin payment adoption among Square's large merchant network.
Square's Bitcoin payment rollout nears completion as of November 9, 2026. For readers following cryptocurrency markets, here is Pluang's market snapshot as of Nov 09, 2026 16:01 WIB: out of 50 major cryptocurrencies priced on Pluang, 6 rose and 43 fell today. Notable movers include SNX at Rp2.831 with a 4.68% decline and a typical hold time of 71 days, UNI at Rp122.135 down 4.57% with 93% sell order activity, and FIL at Rp13.522 down 4.57% with 84% sell order activity.
ISS A/S is actively executing its share buyback program announced in February 2026, aiming to redistribute excess cash to shareholders and reduce share capital. As of early November 2026, the company has repurchased approximately 7.69 million shares ...
AL Sydbank A/S executed transactions to buy back 30,000 shares during week 45 as part of its ongoing share buyback program announced in February 2026, which totals DKK 1.1 billion. The program started in March 2026 and will conclude by January 2027, ...
AL Sydbank A/S continued its share buyback program in week 45, purchasing 30,000 shares at an average price of around 725 DKK, totaling approximately 21.76 million DKK. The buyback program, announced in February 2026 and running until January 2027, a...
Oculis Holding AG announced an in-person and virtual R&D Day on December 8, 2026, to highlight key clinical developments in its late-stage pipeline, including Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmology and neurology. The...
Oculis Holding AG will hold a Research & Development Day on December 8, 2026, to present key clinical progress on its late-stage drug candidates Licaminlimab for dry eye disease and Privosegtor for neuro-ophthalmic conditions including optic neuritis...
